Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing <i>Enterobacter</i> spp, <i>Citrobacter freundii</i>, <i>Morganella morganii</i>, <i>Providencia</i> spp, or <i>Serratia marcescens</i>: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)
Adam G. Stewart(Royal Brisbane and Women's Hospital), Gabriel Yan, Michelle J. Bauer(The University of Queensland), Tiffany Harris‐Brown(The University of Queensland), Naomi Runnegar(Princess Alexandra Hospital), David L. Paterson(The University of Queensland), Barnaby Edward Young(National Centre for Infectious Diseases), Joshua S. Davis(John Hunter Hospital), Brian M. Forde(The University of Queensland), David Chien Lye(Agency for Science, Technology and Research), Gail Brenda Cross, Patrick N. A. Harris(The University of Queensland), Mark D. Chatfield(The University of Queensland), Shirin Kalimuddin(Singapore General Hospital), Mesut Yılmaz(Inonu University), Jeffrey Lipman(The University of Queensland), Sophia Archuleta(National University of Singapore), Po Ying Chia, Andrew Henderson(The University of Queensland), Jyoti Somani, Kellie E. Schneider(John Hunter Hospital), Rumeysa Dinleyici(Istanbul Medipol University)
Cited by 91
Related Papers
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
|Clinical Microbiology Reviews|2015|5.1k
Antimicrobial Resistance in ESKAPE Pathogens
|Clinical Microbiology Reviews|2020|2k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
|Clinical Infectious Diseases|2014|1.1k